Probi
205 SEK -1,44%Vær den første som følger denne virksomhed
Probi is a biotechnology company. The company is particularly focused on the research and development of probiotics, a bacterium that is found in the human intestinal system. The research areas within the company include the gastrointestinal, immune system, metabolic syndrome, and stress and recovery. The company's customers include larger corporate customers active in the food industry. The company was founded in 1991 and is headquartered in Lund.
Omsætning
627,69 mio.
EBIT %
1,8 %
P/E
138,51
Udbytteafkast, %
0,63 %
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
PROB
Daglig lav / høj pris
205 / 205
SEK
Markedsværdi
2,34 mia. SEK
Aktieomsætning
13,53 t SEK
Volumen
66
Seneste videoer
Finanskalender
Delårsrapport
16.07.2024
Delårsrapport
22.10.2024
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Symrise | 69,7 % | 69,7 % |
Fjärde AP-fonden | 9,3 % | 9,3 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Probi's Annual General Meeting 2024
Probi partners with Bower to encourage increased recycling among consumers
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools